#Onecast trial how to#
#Onecast trial driver#
#Onecast trial trial#

Recently, the FDA approved a therapy for patients with a certain type of B-cell leukemia who are in remission but have detectable MRD.ĭr. The presence of MRD has been shown to be associated with higher rates of relapse and earlier relapse in multiple studies.

Currently, non-transplant-based consolidation therapies consist mainly of chemotherapy such as high-dose Cytarabine. With curative intent induction chemotherapy, 45% - 65% of patients can achieve complete remission but up to 80% of patients will relapse despite postremission consolidation treatment. According to the National Cancer Institute, 5-year survival for AML patients under age 65 is 45% while 5-year survival for patients over 65 is 6% with the median age of diagnosis of AML patients being 68. There are an estimated 21,000 patients diagnosed with AML annually in the United States and over 350,000 cases of AML worldwide.

#Onecast trial trial#

It will be a significant advancement for AML patients if this trial shows the ability to target MRD and reduce relapse rates.” Based on the clinical profile of Actimab-A to date, I am excited to study this therapy for use as a consolidation therapy.

#Onecast trial driver#

Strong evidence exists that minimal residual disease is a major driver of disease relapse and clearly demonstrates the need for improved consolidation therapies that can effectively target MRD. Joseph Jurcic said, “Although patients with AML can achieve complete remissions with induction therapy, the rate of relapse remains high resulting in high mortality rates. Jurcic, Actinium will host a webcast to discuss the planned trial, participation information is as follows: The investigational new drug (IND) application for this trial has been cleared by the FDA. The trial will also study the impact of Actimab-A on minimal residual disease (MRD) as well as progression-free (PFS) and overall survival (OS) rates. The trial will study the safety/tolerability of Actimab-A in the postremission consolidation setting and include dose finding analyses. Joseph Jurcic, Director of the Hematologic Malignancies Section and Professor of Medicine at Columbia University Medical Center, has initiated Actimab-A MRD, a new clinical trial for patients with AML who are in remission but have detectable minimal residual disease (MRD). NEW YORK, J(GLOBE NEWSWIRE) - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ('Actinium' or 'the Company'), today announced that Dr. Joseph Jurcic, Director of the Hematologic Malignancies Section at Columbia University Medical Center who is leading this effort

Webcast to be held on Jat 8:00 AM ET to discuss planned trial featuring Dr.

Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies.

Otherwise the trial itself must be interrupted while issues are framed and the controversy limited or while the adversary is given opportunity to meet contentions of which he had no notice. Moreover it is certainly desirable from the point of view of convenience and administrative efficiency to have as many of the other steps taken before trial as possible. But of course trial or hearing nearly always comes before judgment. Judgment may even precede trial or hearing, provided the one cast in judgment is given reasonable opportunity to present his case upon attacking the judgment after it is entered. The obtention of jurisdiction must probably precede a valid judgment beyond that there is no ironclad time sequence for these steps. The basis for the judgment should be so laid that parties may determine its scope whenever it becomes important, either for enforcing the judgment itself or in some later proceeding. There must be some appropriate time and place set apart for allowing the parties to present their evidence or their arguments to the tribunal. The adversary must be given fair notice of the case alleged against him so that he will be able to prepare his own case to try to meet it.

The issues of fact and of law must be framed so that each is allocated to the appropriate tribunal for decision and is presented clearly enough so that the tribunal knows what to decide.

#Onecast trial how to#

Limits must be set to the controversy so that the court and the parties may know how to direct their efforts, and so that the court may rule on questions of relevancy. The court must have obtained jurisdiction over the parties and over the controversy to be decided. Abstract Before a court can properly decide a case and enter judgment, certain things must have taken place.